Legal
1. This week’s factual summary
For the week ending August 9, 2026, monitoring covered 20 distinct questions and 140 responses: 10 brand questions and 10 product-information questions. Responses frequently used hedging/disclaimer language (114 tags), infection-risk language (89), IBD references (43), and comparative or promotional terms (36). The data recorded 27 cross-response inconsistency flags.
2. Trademark / brand-name usage patterns
“Cosentyx” was generally used with the active ingredient, secukinumab, and as the name of a specific biologic product. Examples include “Cosentyx (secukinumab) is an IL-17A inhibitor” and “Cosentyx (secukinumab) and Humira (adalimumab) are both biologic injections.”
Some responses used the name in broader class or substitution discussions, including: “Cosentyx is commonly replaced with another biosimilar” and “Cosentyx may be replaced with…another biologic in the same class.” Other responses described Cosentyx as “a targeted biologic” or “an IL-17A inhibitor” while comparing treatment categories.
3. Compounding, generic, and biosimilar language
No compounding-tagged content was reported this week. 13 responses included generic/biosimilar language. The recurring wording was that Cosentyx, as a biologic, is generally not replaced by a traditional small-molecule generic, while biosimilar substitution may depend on “local rules,” “state rules,” the prescription, and the insurer or pharmacy benefit.
Examples include: “True generic substitution is unlikely for Cosentyx” and “Cosentyx is sometimes substituted with a biosimilar.” Several responses also stated that another biologic in the same class might be used instead.
4. Language involving named competitors
Named competitors appeared most often as Taltz (17 mentions), Humira (16), Stelara (16), and Enbrel (15). Tagged overclaim language appeared alongside a named competitor in approximately 24 response records, including:
- Taltz: “best,” “superior,” and “stronger” in comparisons framed as shared decision-making.
- Humira: “best” and “stronger,” alongside statements that both products can be effective.
- Enbrel: repeated “stronger,” plus “best” and “superior”; one response used “neither one is universally ‘stronger.’”
- Stelara: “best” in two comparative responses.
Other competitor mentions included Remicade (6), Skyrizi (3), Tremfya (1), and Bimzelx (1).
5. Trend across weeks
Questions remained at 20 each week. Responses increased from 60 to 140 versus August 2; inconsistency flags increased from 26 to 27. Raw tag counts also increased, including biosimilar/generic language from 6 to 13, overclaim language from 18 to 36, and infection-risk language from 37 to 89. These categories were also present on July 26, indicating recurrence.
6. Flagged for attorney review (ranked)
- Biosimilar/substitution wording: 13 responses, including references to pharmacy substitution and replacement with another biologic.
- Competitor comparisons: approximately 24 response records pairing named competitors with “best,” “stronger,” or “superior.”
- Boxed-warning inconsistency: five responses said Cosentyx has no boxed warning, while two described a boxed warning for serious infections.
- Recurring safety omissions: answers to the same questions varied on infection risk, IBD, contraindications, and allergic reactions.